Aligos Posts $2.09 Per-Share Q3 Loss as Cash Crunch Looms
ALGS is trading near its 52-week low of $3.98 (13% above the low).
Summary
Aligos reported a third-quarter loss of $2.09 per share, a steep per-share deficit for a company trading near $4.51 with a micro-cap valuation, and the quarterly loss was $21.9M. The company held $31.1M in cash with funding into Q1 2027. The loss lands against a balance sheet already under strain: the last 10-Q showed a $1.5M Q2 loss on $27.8M in licensing revenue. That makes financing the central issue — a loss this size accelerates the need for new capital, likely dilutive at this valuation. The company is also funding pipeline work, including the Phase 1 study of ALG-170675 that dosed its first participant in August. Watch for any announced financing or partnership, with the company's funding now running into Q1 2027.
At the time of this announcement, ALGS was trading at $4.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $3.98 to $13.69. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.